Author & Year | Ref N | Design: N of patients | OGTT Criteria | Marker and thresholds | Sensitivity | Specificity | CASP Score | Notesa |
---|---|---|---|---|---|---|---|---|
Trujillo 2014 | [15] | CC: 4040 NGT, 886 GDM | IADPSG | Fasting blood glucose > A = 80, B = 85 mg/dl | A = 97% B = 93%, | A = 55% B = 78% | 9 | A/C |
Ruetschi 2016 | [31] | COH: 2047 NGT, 251 GDM | IADPSG | Fasting blood glucose > 4.4 mmol⁄ l | 79% | 69% | 8 | C/C |
D’emden 2020 | [32] | COH: 3946 GDM, 22,296 NGT | IADPSG | Fasting blood glucose > 4.6 mmol⁄ l | 54% | 77% | 8 | C/C |
Anjalakshi 2009 | [126] | COH: 713 NGT, 87 GDM | WHO 99 | Non fasting OGTT | 100% | 100% | 8 | A/A: APN |
Kwon 2015 | [35] | COH: 242 GDM,79 NGT | C&C | Glycated haemoglobin (HbA1C) > A = 5.05, B = 5.25% | A = 91% B = 74% | A = 62% B = 77% | 9 | A/C C/C |
Renz 2015 | [36] | COH: 176 NGT,86 GDM | C&C /IADPSG | Glycated haemoglobin (HbA1C) > A = 6.5, B = 5.8, C = 5.0% | A = 7% B = 26% C = 90% | A = 100% B = 95% C = 33% | 11 | D/A D/A A/D |
Rajput 2012 | [34] | COH: 43 GDM, 560 NGT | C&C /IADPSG | Glycated haemoglobin (HbA1C) > A = 5.95, B = 5.45,C = 5.45—5.95%, | A = 29% B = 86% C = 86% | A = 97% B = 61% C = 3% | 9 | B/C |
Siricharoenthai 2020 | [37] | CC: 35 GDM, 79 NGT | NDDG | Glycated haemoglobin (HbA1C) > 5.8% | 17% | 100% | 8 | D/A |
Khan 2020 | [38] | P. COH: 50 GDM, 230 NGT | IADPSG | Glycated haemoglobin (HbA1C) > 6.06% | 70% | 84.8% | 8 | C/B |
Lai 2020 | [40] | R.COH: 3547 GDM, 15,714 NGT | IADPSG | Glycated haemoglobin (HbA1C) > 5.0% | 60.1% | 65.3% | 8 | C/C |
Rayis 2020 | [39] | P. COH: 68 GDM, 272 NGT | IADPSG | Glycated haemoglobin(HbA1C) > A = 4.1%, B = 5.8% | A = 76.5% B = 13.4% | A = 37.8% B = 91.4% | 8 | A = C/D B = D/A |
Ghosh 2017 | [33] | CC: 500 NGT, 127 GDM | C&C | Glycated CD59 = cut-off not specified | 85% | 92% | 10 | B/A: APN |
Cakmak 2019 | [103] | CC: 60 GDM, 75 NGT | C&C | Vascular adhesion protein 1 (VAP-1) > 2.3 | 70% | 65.3% | 8 | C/C |
Tekin 2020 | [127] | CC: 30 NGT, 50 GDM | IADPSG | Signal peptide-CUB-EGF domain-containing protein (SCUBE)-1 > 36.8 ng/mL | 93.1% | 74.2% | 10 | A/C |
Dudzik 2015 | [42] | CC: 20 GDM, 30 NGT | WHO 5.6,8.9,7.8 | LPE(20:1), (20:2), (22:4); LPC(18:2), (20:4), (20:5); LPI(18:2), (20:4); LPS(20:0) and LPA(18:2) | All 100% | All 95% | 9 | A/A: LCPSN |
Sanchez-Garcia 2020 | [128] | P.COH: 38 GDM, 102 NGT | IADPSG | Triglyceride-glucose index (TyG) > 4.69 ng/mL | 89% | 50% | 9 | B/D |
Gingras 2018 | [129] | P.COH: 73 GDM, 1415 NGT | C&C | Fructosamine > 222 _mol/L | 55% | 49% | 9 | C/C |
Koroglu 2019 | [90] | CC: 50 GDM, 30 NGT | IADPSG | Pancreatic-derived factor (PANDER) > 227.2 ng/ml | 100% | 87% | 9 | A/B: LCPSN |
Pan 2019 | [63] | COH: 96 GDM,304 NGT | IADPSG | Betatrophin > 106 pg/mL | 69% | 84% | 9 | C/C |
Fatima 2017 | [20] | CC: 208 GDM, 300 NGT | IADPSG | A = CHEMERIN > 415.49 ng/ml B = LEPTIN > 48.5 ng/ml | A = 96% B = 90% | A = 72% B = 96% | 9 | A = A/C B = A/A: APN |
Yuan 2018 | [29] | COH: 87 GDM, 273 NGT | IADPSG | Ficolin-3/adiponectin ≥ 1.06 | 91% | 97% | 11 | A/A: APN |
Ning 2016 | [83] | CC: 46 GDM,55 NGT | IADPSG | FABP4 > 1.96 ng/mL | 89% | 87% | 10 | B/B: APN |
Wang 2020 | [130] | CC: 60 GDM, 50 NGT | IADPSG | Fatty acid-binding protein 4 (FABP4) > 27.64 Chemerin > 6.78 Chemerin + FABP > 0.71 | 75% 73.3% 80% | 80% 76% 96% | 10 | C/B B/B B/A: APN |
Tawfeek 2017 | [68] | CC: 45 GDM, 45 NGT | IADPSG | Sex hormone binding globulin (SHBG) > 50 nmol/L | 90% | 96% | 10 | A/A: LCPSN |
Amirian 2019 | [66] | P. COH: 63 GDM, 460 NGT | IADPSG | Unconjugated Estriol (UE) > 0.965 MOM | 66.6% | 54.8% | 11 | C/C |
Yilmaz 2014 | [131] | CC: 42 GDM, 68 NGT | C&C | Neutrophil to Lymphocyte Ratio (NLR) > 2.93 | 76% | 94% | 9 | C/B |
Butt 2017 | [132] | CC: 59 GDM, 41 NGT | IADPSG | Cobalamin > 113 pg/mL | 57% | 80% | 10 | C/B |
Giacobbe 2016 | [133] | CC: 75 GDM,48 NGT | IADPSG | High mobility group box 1 > 1.85 ng/ml | 81% | 96% | 11 | B/A:APN |
Shaas 2017 | [82] | CC: 50 GDM,50 NGT | IADPSG | risk factors + HBA1c + SHBG + PAPP-A + CRP | 75% | 91% | 10 | C/A |
Thériault 2016 | [81] | CC: 264 GDM,528 NGT | IADPSG | previous GDM, family history of diabetes and soft drink intake before pregnancy + HbA1c + SHBG + BMI | 69% | 90% | 12 | C/A |
Tantanasis 2010 | [14] | CC: 20 GDM, 15 NGT | WHO 99 | Fetus maximum subcutaneous fat tissue thickness > 3.950 mm at HC, 4.550 mm at AC and 4.700 mm at TS | 100% | 100% | 11 | A/A: LCPSN |
Kansu-Celick 2018 | [108] | COH: 46 GDM,177 NGT | C&C | Maternal Subcutaneous adipose tissue (SAT) thickness > 16.75 mm | 72%, | 58% | 9 | C/C |
Aydin 2020 | [115] | CC: 60 GDM, 60 NGT | C&C /IADPSG | Fetal epicardial fat thickness (fEFT) > 0.95 mm | 65% | 88% | 8 | C/B |
İlhan 2018 | [111] | CC: 33 GDM, 64 NGT | IADPSG | Fetal liver volume (FLV) > 32.72 cm3 | 79% | 56% | 9 | C/C |
Perovic 2012 | [117] | COH: 33 GDM, 77 NGT | C&C | Ultrasound Gestational Diabetes Screening Score (UGDS)c > 4 | B = 91%, | B = 90% | 11 | A/A: APN |